Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer - Schwartzberg, L S; Wang, G; Somer, B G (Clin Breast Cancer, 2014)
et al.